13F filer · CIK 1855655
Paradigm Biocapital Advisors LP
NEW YORK, NY · filing since Q4 2021 · last filing Aug 14, 2026
Reported value
$5.3B
+$446.3M vs prior
Positions
28
New / sold out
7 / 14
Added / reduced
12 / 7
Turnover
23.1%
buys $1.2B · sells $1.7B
Top-10 weight
75.2%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | SPYRE THERAPEUTICS INC | +1,883,512 | +96.2% | +$167.2M |
| New | ALNYLAM PHARMACEUTICALS INC | +480,000 | – | +$144.5M |
| Added | GENMAB A/S | +5,165,295 | +64.8% | +$141.9M |
| New | MBX BIOSCIENCES INC | +2,508,015 | – | +$138.4M |
| Added | EDGEWISE THERAPEUTICS INC | +2,850,417 | +38.7% | +$115.8M |
| Added | NUVALENT INC | +600,000 | +11.3% | +$74.1M |
| Added | TANGO THERAPEUTICS INC | +2,347,844 | +58.6% | +$73.4M |
| Added | VIRIDIAN THERAPEUTICS INC | +3,574,895 | +113.5% | +$65.7M |
| New | JADE BIOSCIENCES INC | +2,857,405 | – | +$63.5M |
| New | ACHIEVE LIFE SCIENCE INC | +4,951,856 | – | +$32.3M |
9 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | ARCELLX INC | -5,774,016 | -100.0% | $-663.0M |
| Reduced | VAXCYTE INC | -2,665,168 | -55.6% | $-154.9M |
| Sold out | CENTESSA PHARMACEUTICALS PLC | -3,574,048 | -100.0% | $-142.0M |
| Sold out | TERNS PHARMACEUTICALS INC | -2,216,499 | -100.0% | $-116.9M |
| Sold out | CYTOKINETICS INC | -1,480,857 | -100.0% | $-97.6M |
| Sold out | ABIVAX SA | -772,473 | -100.0% | $-86.0M |
| Sold out | MAZE THERAPEUTICS INC | -2,744,399 | -100.0% | $-81.9M |
| Sold out | SCHOLAR ROCK HLDG CORP | -1,226,080 | -100.0% | $-60.3M |
| Sold out | MIRUM PHARMACEUTICALS INC | -625,000 | -100.0% | $-57.7M |
| Reduced | REVOLUTION MEDICINES INC | -294,380 | -4.4% | $-55.1M |
11 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INCCOM | 6,361,323 | $1.2B | 22.31% |
| 2 | NUVALENT INCCOM | 5,924,433 | $731.7M | 13.70% |
| 3 | EDGEWISE THERAPEUTICS INCCOM | 10,215,455 | $415.1M | 7.77% |
| 4 | GENMAB A/SSPONSORED ADS | 13,133,131 | $360.8M | 6.76% |
| 5 | SPYRE THERAPEUTICS INCCOM NEW | 3,840,778 | $341.0M | 6.38% |
| 6 | APOGEE THERAPEUTICS INCCOM | 1,576,385 | $209.2M | 3.92% |
| 7 | ORUKA THERAPEUTICS INCCOM | 2,144,526 | $204.1M | 3.82% |
| 8 | TANGO THERAPEUTICS INCCOM | 6,357,523 | $198.7M | 3.72% |
| 9 | BELITE BIO INCSPONSORED ADS | 1,232,877 | $189.8M | 3.55% |
| 10 | ERASCA INCCOM | 9,550,000 | $175.0M | 3.28% |
18 more rows. Subscribe for $29/month to see every row, download the data and use the API.